|
|
Article: CyDex Series B Nets $17M For Internal Drug Programs.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Senior Staff Writer
CyDex Inc. raised $17 million in its Series B round from an international syndicate of venture capital investors.
The Lenexa, Kan.-based company said the funds would allow it to move ahead with several new pharmaceutical products that it plans to advance internally and also out-license for further development. Through a couple of arms of its business model, CyDex is developing a pipeline of products based on its delivery technology, Captisol, which it also out-licenses for use in other companies' drug programs.
That element of the business has produced the most tangible evidence of the technology's viability to date - two ...